Literature DB >> 14687940

The neutralization of pseudorabies virus by anti-alpha-galactocyl natural antibody in normal serum.

Sunao Hayashi1, Seiji Ogawa, Yasuhiro Takashima, Haruki Otsuka.   

Abstract

Pseudorabies virus (PrV), a member of herpesviridae alphaherpes subfamily, can infect human cells in vitro. However, the transmission to Old World primates including humans is strongly restricted. In this study, we report the neutralizing activity of normal human serum against PrV grown in CPK cells derived from pig. PrV grown in all Old World primates-derived cells, which was tested in this study, were not neutralized by normal human serum. The virion of PrV grown in CPK cells harbored Galalpha1-3Galbeta1-4GlcNAc-R (alpha-gal epitope) on its surface, while PrV grown in Vero cells did not. Depletion of antibodies reacting to surface antigens of CPK cells negated the neutralization activity of human serum. Blockade of anti-alpha-gal antibodies by adding soluble Galalpha1-3Gal to normal human serum also prevent the inactivation of PrV grown in CPK cells. Although normal swine serum did not neutralize PrV grown in CPK cells, swine serum supplemented with exogenous anti-alpha-gal antibodies did. These results indicate that anti-alpha-gal antibodies in normal human serum contribute to the neutralization of PrV. Anti-alpha-gal antibodies in normal human serum may prevent transmission of PrV into humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14687940     DOI: 10.1016/j.virusres.2003.09.008

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.

Authors:  Lauren M Hook; John M Lubinski; Ming Jiang; Michael K Pangburn; Harvey M Friedman
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

2.  Possible role of a cell surface carbohydrate in evolution of resistance to viral infections in old world primates.

Authors:  Idalia A Rodriguez; Raymond M Welsh
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

Review 3.  Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products.

Authors:  Carol Marcus-Sekura; James C Richardson; Rebecca K Harston; Nandini Sane; Rebecca L Sheets
Journal:  Biologicals       Date:  2011-10-13       Impact factor: 1.856

4.  Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.

Authors:  Lisa Pipperger; Iris Koske; Nicole Wild; Brigitte Müllauer; Daniela Krenn; Heribert Stoiber; Guido Wollmann; Janine Kimpel; Dorothee von Laer; Zoltán Bánki
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

Review 5.  Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.

Authors:  Uri Galili
Journal:  Vaccine       Date:  2020-08-19       Impact factor: 3.641

Review 6.  SARS-CoV-2 replicating in nonprimate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.

Authors:  Ji-Ming Chen
Journal:  J Med Virol       Date:  2020-08-02       Impact factor: 20.693

Review 7.  Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as "Achilles' Heel" of Viruses Contributing to Anti-Viral Immune Protection.

Authors:  Uri Galili
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

Review 8.  Live unattenuated vaccines for controlling viral diseases, including COVID-19.

Authors:  Ji-Ming Chen
Journal:  J Med Virol       Date:  2020-09-29       Impact factor: 20.693

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.